Nguyen Minhtri K, Bandaru Dhiresh, Nguyen Minh-Kevin
Medicine, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, USA.
Medicine, University of California, Riverside School of Medicine, Riverside, USA.
Cureus. 2025 Aug 7;17(8):e89569. doi: 10.7759/cureus.89569. eCollection 2025 Aug.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphorus metabolism caused by increased secretion of fibroblast growth factor 23 (FGF23) by small mesenchymal tumors. In this article, we reported a patient with chronic refractory hypophosphatemia due to TIO who is treated with burosumab, a monoclonal antibody that targets and blocks the activity of FGF23. Treatment with burosumab led to the resolution of his refractory hypophosphatemia, but this was complicated by the development of secondary hyperparathyroidism. This article reports a rare case of hyperparathyroidism induced by burosumab in a patient with TIO.
肿瘤诱导的骨软化症（TIO）是一种罕见的副肿瘤综合征，由小间充质肿瘤分泌的成纤维细胞生长因子23（FGF23）增加导致磷代谢异常。在本文中，我们报告了一名因TIO导致慢性难治性低磷血症的患者，该患者接受了布罗索尤单抗治疗，布罗索尤单抗是一种靶向并阻断FGF23活性的单克隆抗体。布罗索尤单抗治疗使他的难治性低磷血症得到缓解，但出现了继发性甲状旁腺功能亢进的并发症。本文报道了一例TIO患者因布罗索尤单抗诱发甲状旁腺功能亢进的罕见病例。
